Patents Assigned to Krisani Biosciences (P) Ltd.
-
Patent number: 8445707Abstract: The disclosure herein provides the compounds of Formulas 1, 2 and 3 and their pharmaceutical acceptable salts, as well as polymorphs, solvates, and hydrates thereof. These salts may be formulated as pharmaceutical compositions. The pharmaceutical compositions may be formulated for oral administration, transdermal administration, and/or injection. Such compositions may be used for the treatment of metabolic conditions, cystinosis, non-alcoholic Steatohepatitis, hypertriglyceridemia, and/or neurodegenerative disorders, and/or their associated complications.Type: GrantFiled: October 10, 2012Date of Patent: May 21, 2013Assignee: Krisani Biosciences (P) Ltd.Inventor: Mahesh Kandula
-
Patent number: 8283375Abstract: The disclosure herein provides a compound of formula 1. The disclosure also provides a method of synthesizing the compound of formula 1. The compound of formula 1 or its pharmaceutical acceptable salts, as well as polymorphs, solvates, and hydrates thereof may be formulated as pharmaceutical composition. The pharmaceutical composition of compound of formula 1 or the final compound may be formulated for non-invasive peroral, topical (example transdermal), enteral, transmucosal, targeted delivery, sustained release delivery, delayed release, pulsed release and parenteral methods. Such compositions may be used to treat chronic pain manifested with chronic diseases or its associated complications. The compound may also be offered as a kit.Type: GrantFiled: March 13, 2012Date of Patent: October 9, 2012Assignee: Krisani Biosciences (P) Ltd.Inventor: Mahesh Kandula
-
Publication number: 20120172421Abstract: The disclosure herein provides a compound of formula 1. The disclosure also provides a method of synthesizing the compound of formula 1. The compound of formula 1 or its pharmaceutical acceptable salts, as well as polymorphs, solvates, and hydrates thereof may be formulated as pharmaceutical composition. The pharmaceutical composition of compound of formula 1 or the final compound may be formulated for non-invasive peroral, topical (example transdermal), enteral, transmucosal, targeted delivery, sustained release delivery, delayed release, pulsed release and parenteral methods. Such compositions may be used to treat chronic pain manifested with chronic diseases or its associated complications. The compound may also be offered as a kit.Type: ApplicationFiled: March 13, 2012Publication date: July 5, 2012Applicant: KRISANI BIOSCIENCES (P) LTDInventor: Mahesh Kandula
-
Publication number: 20120022147Abstract: The disclosure herein provides a composition compound of formula 1. The disclosure also provides a method of synthesizing the compound of formula 1. The compound of formula 1 or its pharmaceutical acceptable salts, as well as polymorphs, solvates, and hydrates thereof may be formulated as pharmaceutical composition to be used for treatment of pain. The pharmaceutical composition of compound of formula 1 or the final compound may be formulated for non-invasive peroral, topical (example transdermal), enteral, transmucosal, targeted delivery, sustained release delivery, delayed release, pulsed release and parenteral methods. Such compositions may be used to treat chronic pain manifested with chronic diseases or its associated complications. The compound of formula 1 may also be offered as a kit.Type: ApplicationFiled: September 9, 2011Publication date: January 26, 2012Applicant: KRISANI BIOSCIENCES (P) LTDInventor: Mahesh Kandula
-
Publication number: 20110300190Abstract: The disclosure herein provides a compound of formula I or its pharmaceutical acceptable salts, as well as polymorphs, solvates, and hydrates thereof. The steps of synthesis of compound of formula I is described. These salts may be formulated as pharmaceutical compositions. The pharmaceutical compositions may be formulated for oral administration, transdermal administration, or injection. Such compositions may be used to treatment of metabolic condition or neurodegenerative disorders or its associated complications.Type: ApplicationFiled: June 3, 2011Publication date: December 8, 2011Applicant: KRISANI BIOSCIENCES (P) LTDInventor: MAHESH KANDULA
-
Publication number: 20110281893Abstract: The instant application provides the disclosure for a compound of formula I, synthesis of compound of formula I and its pharmaceutical acceptable salts, as well as its polymorphs, solvates, and hydrates thereof. The pharmaceutically acceptable salt may be formulated for oral administration, systemic administration, transdermal administration and injection. The compound of formula I and its pharmaceutical compositions may be used to treat cancer in mammal.Type: ApplicationFiled: May 9, 2011Publication date: November 17, 2011Applicant: KRISANI BIOSCIENCES (P) LTDInventor: Mahesh Kandula